Treatment of zygomycosis: Current and new options

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue SUPPL. 1, 2008, Pages 35-40

  Rogers, Thomas R ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Diabetes mellitus; Haematopoietic stem cell transplant; Liposomal amphotericin B; Posaconazole

Indexed keywords

ANTIFUNGAL AGENT; POSACONAZOLE; TRIAZOLE DERIVATIVE;

ANTIFUNGAL RESISTANCE; DRUG EFFECT; HUMAN; MUCORMYCOSIS; PHYSIOLOGY; REVIEW;

ANTIFUNGAL AGENTS; DRUG RESISTANCE, FUNGAL; HUMANS; TRIAZOLES; ZYGOMYCOSIS;

EID: 41949132566     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm429     Document Type: Article

References (42)

1. Sugar AM. Agents of mucormycosis and related species. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of nfectious Diseases, 6th edn. Philadelphia: Elsevier, 2005; 2973-84.
2. Chayakulkeeree M, Ghannoum MA, Perfect JR. Zygomycosis: he re-emerging fungal infection. Eur J Microbiol Infect Dis 2006; 25: 15-29
3. Rees JR, Pinner RW, Hajjeh RA et al. The epidemiologic feaures of invasive mycotic infection in the San Francisco bay area 1992-1993: results of a population-based laboratory active surveillence. Clin Infect Dis 1998; 27: 1138-47.
4. Gil-Lamaignere C, Simitsopoulou M, Roilides E et al. Interferon gamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medi-cally important zygomycetes. J Infect Dis 2005; 191: 1180-7.
5. Shoham S, Levitz SM. The immune response to fungal infections. Br J Haematol 2005; 129: 569-82.
6. Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005; 18: 556-69.
7. Chamilos G, Marom EM, Lewis RE et al. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis 2005; 41:60-6.
8. Chamilos G, Luna M, Lewis RE et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006; 91: 986-9.
9. Roden MM, Zaoutis TE, Buchanan WL et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634-53.
10. Sims CR, Ostrosky-Zeichner L. Contemporary treatment and outcomes of zygomycosis in a non-oncologic tertiary care center. Arch Med Res 2007; 38:90-3.
11. Pagano L, Ricci P, Tonso A et al. Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. Br J Haematol 1997; 99: 331-6.
12. Tonso A, Ricci P, Cenacchi A et al. Invasive infections by filamentous mycetes in adult patients with haematological neoplastic diseases (polycentric and retrospective study of 162 cases). Haematologica 1993; 78 Suppl IV: 24.
13. Kontoyiannis DP, Lionakis MS, Lewis RE et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005; 191: 1350-60.
14. Trifilio SM, Bennett CL, Yarnold PR et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007; 39: 425-9.
15. Marr KA, Carter RA, Crippa F et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-17.
16. Almyroudis NG, Sutton DA, Fothergill AW et al. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother 2007; 51: 2587-90.
17. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi: Approved Standard M38-A. NCCLS, Wayne, PA, USA, 2002.
18. Sabatelli F, Patel R, Mann PA et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006; 50: 2009-15
19. Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 2004; 42: 4419-31.
20. Torres-Narbona M, Guinea J, Martinez-Alarcon J et al. In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole and voriconazole against 45 clinical isolates of zygomycetes: compari-son of CLSI M38-A, Sensititre YeastOne, and the Etest. Antimicrob Agents Chemother 2007; 51: 1126-9.
21. Guembe M, Guinea J, Pelaez T et al. Interaction between posaconazole and caspofungin against clinical zygomycetes: a synergistic effect. Antimicrob Agents Chemother 2007; 51: 3547-8.
22. Kwon DS, Mylonakis E. Posaconazole: a new broad-spectrum antifungal agent. Expert Opin Pharmacother 2007; 8: 1167-78.
23. Greenberg RN, Mullane K, van Burik J-AH et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob agents Chemother 2006; 50: 126-33.
24. Van Burik J-A, Hare RS, Solomon HF et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006; 42: e61-5.
25. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
26. Barchiesi F, Spreghini E, Santinelli A et al. Posaconazole prophylaxis in experimental systemic zygomycosis. Antimicrob Agents Chemother 2007; 51:73-7.
27. Cornelly OA, Maertens J, Winston DJ et al. Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348-59.
28. Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-47.
29. Greenberg RN, Scott LJ, Vaughn HH et al. Zygomycosis (mucormycosis): emerging clinical importance and new treatments. Curr Opin Infect Dis 2004; 17: 517-25.
30. Gleissner B, Schilling A, Anagnostopolous I et al. Improved outcome of zygomycosis in patients with hematological disease. Leuk Lymphoma 2004; 45: 1351-60.
31. Walsh TJ, Hiemenz JW, Seibel NL et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26: 1383-96.
32. Richardson M. AmBisome: adds to the body of knowledge and familiarity of use. Acta Biomed 2006; 77 Suppl 4: 3-11.
33. Revankar SG, Hasan MS, Smith JW. Cure of disseminated zygomycosis with cerebral involvement using high dose liposomal amphotericin B and surgery. Med Mycol 2007; 45: 183-5.
34. Stark D, Milliken S, Marriott D et al. Rhizopus microsporus var. rhizopodiformis sinus-orbital zygomycosis in an immunosuppressed patient: successful treatment with posaconazole after a complicated clinical course. J Med Microbiol 2007; 56: 699-701.
35. Page RL, II, Schwiesow J, Hilts A. Posaconazole as salvage therapy in a patient with disseminated zygomycosis: case report and review of the literature. Pharmacotherapy 2007; 27: 290-8.
36. Rutar T, Cockerham KP. Periorbital zygomycosis (mucormyco-sis) treated with posaconazole. Am J Ophthalmol 2006; 142: 187-8.
37. Johnson MD, Perfect JR. Combination antifungal therapy: what can and should we expect? Bone Marrow Transplant 2007; 40: 297-306.
38. Vazquez L, Mateos JJ, Sanz-Rodriguez C et al. Successful treat- ment of rhinocerebral zygomycosis with a combination of caspofungin and liposomal amphotericin B. Haematologica 2005; 90 (12 Suppl): ECR39.
39. Rickerts V, Atta J, Herrmann S et al. Successful treatment of disseminated mucormycosis with a combination of liposomal amphoter-icin B and posaconazole in a patient with acute myeloid leukaemia. Mycoses 2006; 49 Suppl 1: 27-30.
40. Spellberg B, Fu Y, Edwards JE Jr et al. Combination therapy with amphotericin B lipid complex and caspofungin acetate of dissemi-nated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother 2005; 49: 830-2.
41. John BV, Chamilos G, Kontoyiannis DP. Hyperbaric oxygen as an adjunctive treatment for zygomycosis. Clin Microbiol Infect 2005; 11: 515-7.
42. Reed C, Ibrahim A, Edwards JE Jr et al. Deferasirox, an iron chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother 2006; 50: 3968-9.